Research Article

Assessment of the E-Selectin rs5361 (561A>C) Polymorphism and Soluble Protein Concentration in Acute Coronary Syndrome: Association with Circulating Levels

Table 1

Demographic and clinical characteristics in ACS according to rs5361 (561A>C) E-selectin polymorphism following a dominant genetic model.

561A>C E-selectin in ACS
All patients
(%)
A/A
(%)
A/C + C/C
(%)
value
Average ± SE

Demographics
 Age, years63 ± 11.863.24 ± 11.72961.13 ± 12.3120.364
 Gender male/female226/57
(79.9/20.1)
209/51
(80.4/19.6)
17/6
(73.9/26.1)
0.307
 Glucose (mg/dL)161.626 ± 70.74158.884 ± 67.7846205.5 ± 136.47160.556
 Triglycerides (mg/dL)171.167 ± 41.4894171.167 ± 41.48940 ± 0
 Cholesterol (mg/dL)181 ± 53.075181 ± 53.0750 ± 0
 CK (IU/L)924.71 ± 1509.328910.45 ± 1540.6891093.07 ± 1097.8920.099
 CK-MB (IU/L)110.37 ± 167.070109.93 ± 170.653116.05 ± 114.3810.265
 Troponin T (ng/mL)7.2212 ± 14.102676.7461 ± 14.3023612.3385 ± 10.897420.118
Diagnosis
 UA29 (10.2)26 (10.0)3 (13.0)0.427
 STEMI214 (75.6)200 (76.9)14 (60.9)0.076
 NSTEMI40 (14.1)34 (13.1)6 (26.1)0.86
Risk factor
 Obesity112 (39.6)100 (38.5)12 (52.2)0.143
 DM2131 (39.9)123 (47.3)8 (34.8)0.175
 DYS117 (41.3)107 (41.2)10 (43.5)0.497
 HBP172 (60.8)159 (61.2)13 (56.5)0.411
Treatment
 AA224 (79.2)208 (80.0)16 (69.6)
 ACE inhibitors147 (51.9)136 (52.3)11 (47.8)
 AnA271 (95.8)249 (95.8)22 (95.7)
 ARB33 (11.7)31 (11.9)2 (8.7)
 CCB4 (1.4)4 (1.5)0 (0)
 Antiarrhythmics5 (1.8)4 (1.5)1 (4.3)
 Diuretic66 (23.3)60 (23.1)5 (21.7)
 Antilipid therapy233 (82.3)213 (81.9)20 (87.0)

Quantitative and qualitative data were evaluated by Mann-Whitney test and exact test, respectively. CK: creatine phosphokinase; CK-MB: creatine phosphokinase MB; UA: unstable angina; STEMI: ST elevation myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; DM2: type 2 diabetes mellitus; DYS: dyslipidemia; HBP: high blood pressure; AA: antithrombin agents; AnA: antiplatelet agents; ARB: angiotensin II receptor blockers; CCB: calcium channel blockers; SE: standard error.